AstraZeneca AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-based biopharmaceutical company focused on the discovery, development and commercialization of prescription drugs, primarily for the treatment of diseases in three therapeutic areas – oncology, cardiovascular, renal and metabolic, and respiratory and immune. Headquartered in Cambridge, UK, AstraZeneca operates in more than 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the company on Twitter @AstraZeneca. Today`s agreement with the Department of Health and Human Services (HHS) and the Department of Defense (DoD) builds on an agreement reached in October 2020 to support the advanced development of AZD7442 and provide the first 100,000 doses of the LAAB combination. It included the option to purchase additional doses in 2021. The company also entered into a separate agreement to supply 100,000 doses to the Department of Defense, which would increase the potential U.S. supply of AZD7442 to 700,000 in 2021. AstraZeneca, based in Cambridge, England, said it has reached agreements for at least 400 million doses of the vaccine and secured a production capacity of 1 billion doses, with initial deliveries set to begin in September. The initial doses, which are manufactured in the United States, are in the possession of the federal government under the terms of agreements with drug manufacturers, and the Biden administration has been urged by allies around the world to release AstraZeneca`s injections for immediate use. Biden also received direct requests from Canadian Prime Minister Justin Trudeau and Mexican President Andrés Manuel López Obrador to buy U.S.-made vaccines. AstraZeneca has signed the delivery of 400 million cans under its first supply contracts. The deal with the US – through HHS`s BARDA agency – follows a UK deal.
The pact was unveiled on Sunday for a total of 100 million doses. This gives the U.S. the delivery of about 300 million doses of vaccine starting this fall. AstraZeneca has amended an existing agreement with the U.S. government to provide up to 500,000 additional doses of AZD7442, a long-acting antibody (LAAB) combination that is in late-stage development for the prevention and treatment of COVID-19. Financial Considerations The value of the expanded agreement is $205 million and depends on AZD7442 obtaining emergency authorization from the Food and Drug Administration for post-exposure prophylaxis – the ability to prevent COVID-19 in people who have confirmed their exposure to the SARS-CoV-2 virus. The Biomedical Advanced Research and Development Authority (BARDA), which is part of the HHS office of the Assistant Secretary for Preparedness and Response, worked with the Executive Office of the DoD Joint Program for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) and the Army Contracts Command to provide funds for the purchase of the additional doses. Together, the total value of the current agreements with the U.S. government for the development and delivery of the AZD7442 in 2021 is approximately $726 million. The expanded agreement is not expected to impact the Company`s financial guidance for 2021. Under the terms of the agreement, AstraZeneca agreed to pay the 318 employees $560,000 in arrears and interest. In addition to production contracts with the UK and US, AstraZeneca is in talks with other governments.
He continues to work with international vaccine and health groups for possible global distribution and discusses options with the Serum Institute of India, the world`s largest vaccine distributor. The OFCCP implements Presidential Decree 11246, Article 503 of the Rehabilitation Law of 1973 and the Law of 1974 on Assistance for the Readjustment of Vietnam-Era Veterans. On Sunday, the UK Secretary of State for The Economy, Energy and Industrial Strategy, Alok Sharma, said the manufacturer of the drug had agreed to distribute 30 million doses in the UK in September, for a total of 100 million. The UK “will be the first to have access to it” if the vaccine succeeds, Sharma said at a press briefing. The fate of these doses of AstraZeneca`s vaccine is the subject of intense debate among the White House and federal health officials, with some saying the government should let them go abroad where they are desperately needed, while others are unwilling to abandon them, according to senior administration officials. The company is now grappling with another fear of safety. As a precautionary measure, health authorities in Denmark, Norway and Iceland on Thursday suspended the use of AstraZeneca`s vaccine following several reports of severe blood clots across the continent. Just days after Moderna announced positive initial results for its potential COVID-19 vaccine, AstraZeneca has taken centre stage again. .